Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Post-Mkt 05-19 19:02:57 EDT

28.21

-0.34

-1.19%

盘后27.99

-0.22-0.78%

18:13 EDT

High28.70	Low27.85	Vol4.13M
Open28.47	D1 Closing28.55	Amplitude2.98%
Mkt Cap20.19B	Tradable Cap13.17B	Total Shares715.70M
T/O116.86M	T/O Rate0.88%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":28.21,"timestamp":1779220800000,"preClose":28.55,"halted":0,"volume":4132383,"hourTrading":{"tag":"盘后","latestPrice":27.99,"preClose":28.21,"latestTime":"18:13 EDT","volume":406201,"amount":11458151.928884,"timestamp":1779228831494,"change":-0.22,"changeRate":-0.007799,"amplitude":0.035448},"delay":0,"changeRate":-0.011908931698774076,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"Post-Mkt","change":-0.34,"latestTime":"05-19 19:02:57 EDT","open":28.47,"high":28.7,"low":27.85,"amount":116858088.55146,"amplitude":0.029772,"askPrice":28,"askSize":299,"bidPrice":27.4,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779235200000},"marketStatusCode":4,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":28.55,"preHourTrading":{"tag":"盘前","latestPrice":28.24,"preClose":28.55,"latestTime":"09:28 EDT","volume":109,"amount":3084.789925,"timestamp":1779197302537,"change":-0.31,"changeRate":-0.010858,"amplitude":0.011909},"postHourTrading":{"tag":"盘后","latestPrice":27.99,"preClose":28.21,"latestTime":"18:13 EDT","volume":406201,"amount":11458151.928884,"timestamp":1779228831494,"change":-0.22,"changeRate":-0.007799,"amplitude":0.035448},"volumeRatio":0.530002,"impliedVol":0.2951,"impliedVolPercentile":0.2669},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"1188991853","title":"Earning Preview: Roivant Sciences Ltd. revenue is expected to decrease by 92.94%, institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1188991853","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1188991853?lang=en_us&edition=fundamental","pubTime":"2026-05-13 10:12","pubTimestamp":1778638368,"startTime":"0","endTime":"0","summary":"Abstract Roivant Sciences Ltd. will report fiscal results on May 20, 2026 Pre-Market; this preview summarizes consensus revenue, margin and EPS expectations, last quarter’s results, and analyst views...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Roivant Sciences Ltd. revenue is expected to decrease by 92.94%, institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636687218","title":"A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2636687218","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636687218?lang=en_us&edition=fundamental","pubTime":"2026-05-19 23:20","pubTimestamp":1779204005,"startTime":"0","endTime":"0","summary":"Recent commentary around Roivant Sciences (ROIV) has focused on two catalysts: increasing attention on its IMVT-1402 program in myasthenia gravis, and the company’s upcoming Q4 2026 earnings report on May 20.\nSee our latest analysis for Roivant Sciences.\nAt a share price of $28.55, Roivant has seen short term share price pressure, with the 1 day and 30 day share price returns both down. At the same time, a 90 day share price return of 5.39% and a 1 year total shareholder return of 163.38%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/a-look-at-roivant-sciences-roiv-valuation-as-imvt-1402-and-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635803717","title":"Roivant Sciences price target raised to $29.50 from $29 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635803717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635803717?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:20","pubTimestamp":1778761211,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $29.50 from $29 and keeps a Neutral rating on the shares. The fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-29-50-from-29-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-29-50-from-29-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237579","title":"Immunovant to report fourth-quarter, fiscal-year results, give business update on conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237579?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530334,"startTime":"0","endTime":"0","summary":"Immunovant schedules fourth-quarter and fiscal-year results for period ended March 31, 2026, with business update at 8:00 a.m. ET on May 20, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8KT5GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","SG9999014005.SGD","ROIV","NDAQ","IMVT","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232248","title":"Roivant schedules quarterly, fiscal-year results call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232248","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232248?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:08","pubTimestamp":1778530124,"startTime":"0","endTime":"0","summary":"Roivant scheduled live conference call, webcast for 8:00 a.m. ET May 20, 2026 to report fourth-quarter results, full-year results for fiscal year ended March 31, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8QSFRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","ROIV","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4007","BK4588","BK4112","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634912232","title":"Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634912232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634912232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA5651WL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623017","title":"Immunovant director Robert Graham Susman sells 2,502 shares for $67,988.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623017","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623017?lang=en_us&edition=fundamental","pubTime":"2026-05-02 06:40","pubTimestamp":1777675258,"startTime":"0","endTime":"0","summary":"Immunovant director Robert Graham Susman sold 2,502 shares of common stock on May 1, 2026.Sale priced at weighted average USD 27.17 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL5l0JhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","IMVT","BK4585","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629986663","title":"Zura Bio names Marlyn Mathew principal financial, accounting officer after CFO exit","url":"https://stock-news.laohu8.com/highlight/detail?id=2629986663","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629986663?lang=en_us&edition=fundamental","pubTime":"2026-04-24 05:06","pubTimestamp":1776978384,"startTime":"0","endTime":"0","summary":"Zura Bio separated Chief Financial Officer Eric Hyllengren on April 20, 2026.Separation was not tied to financial or operating results or to disputes over operations or reporting practices.Board named Vice President, Finance and Accounting Marlyn Mathew as principal accounting officer.Mathew also took on principal financial officer duties.Mathew joined Zura Bio in June 2022; previously served as controller at Immunovant from 2019 to May 2022.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL233CpF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMVT","BK4585","ROIV","ZURA","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629477436","title":"Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629477436","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629477436?lang=en_us&edition=fundamental","pubTime":"2026-04-21 06:27","pubTimestamp":1776724078,"startTime":"0","endTime":"0","summary":"Roivant Sciences CEO Matthew Gline disclosed sale of 289,774 common shares on April 16, 2026.Shares sold at weighted average price of USD 29.16.Directly held stake fell to 16,736,116 common shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL2VlrKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant CEO Matthew Gline disposes of 289,774 common shares for $8.45 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628434730","title":"Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2628434730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628434730?lang=en_us&edition=fundamental","pubTime":"2026-04-18 20:17","pubTimestamp":1776514651,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Roivant Sciences, with a price target of $35.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-gets-a-buy-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2133065610.SGD","BK4127","BK4588","LU0234570918.USD","LU0106831901.USD","LU2028103732.USD","LU2271345857.HKD","LU2357305700.SGD","LU1989772923.USD","LU1732799900.SGD","LU0006306889.USD","LU0795875086.SGD","BK4139","LU0225283273.USD","LU0912757837.SGD","LU1791710400.SGD","LU1548497426.USD","LU2347655156.SGD","LU0267386448.USD","LU1989772840.SGD","LU2089283258.USD","ROIV","LU1244550577.SGD","LU0098860793.USD","LU0971096721.USD","LU2111349929.HKD","LU1244550494.USD","LU0528227936.USD","LU0882574139.USD","LU1720051017.SGD","IE00BZ1G4Q59.USD","LU0158827948.USD","BK4585","LU1244550221.USD","LU1363072403.SGD","LU1732800096.USD","LU0314104364.USD","LU0795875169.SGD","LU2089284900.SGD","BK4581","IE00BKVL7J92.USD","LU1720051108.HKD","LU2023251221.USD","LU0158827781.USD","LU0557290698.USD","LU1162221912.USD","LU1791710582.SGD","BK4007","BK4504","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628009210","title":"Roivant Sciences Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2628009210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628009210?lang=en_us&edition=fundamental","pubTime":"2026-04-17 01:37","pubTimestamp":1776361020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 13:37 ET (17:37 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627500542","title":"Roivant Sciences Ltd : Piper Sandler Raises Target Price to $40 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2627500542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627500542?lang=en_us&edition=fundamental","pubTime":"2026-04-16 11:02","pubTimestamp":1776308523,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y0Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626456341","title":"Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278","url":"https://stock-news.laohu8.com/highlight/detail?id=2626456341","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626456341?lang=en_us&edition=fundamental","pubTime":"2026-04-11 06:01","pubTimestamp":1775858465,"startTime":"0","endTime":"0","summary":"Roivant Sciences Chief Accounting Officer Jennifer Humes sold 13,538 common shares on April 8, 2026.Sale priced at USD 28.37 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL5PxvDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Chief Accounting Officer Jennifer Humes disposes 13,538 shares for $384,278","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625495186","title":"Roivant Sciences price target raised to $34 from $30 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625495186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625495186?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:34","pubTimestamp":1775572453,"startTime":"0","endTime":"0","summary":"Jefferies analyst Dennis Ding raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $30 and keeps a Buy rating on the shares. A key...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-30-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-34-from-30-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624694383","title":"Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624694383","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624694383?lang=en_us&edition=fundamental","pubTime":"2026-04-04 15:17","pubTimestamp":1775287059,"startTime":"0","endTime":"0","summary":"In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint.\nThe brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab.\nWe’ll now examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","BK4007","BK4551","BK4585","BK4139","BK4588","AIPO","AI","AIYY","ROIV","BK4587","BK4023","CHAT","BK4543","ARTY","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664954","title":"Immunovant CEO Eric Venker disposes of common shares worth $8.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664954","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664954?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:33","pubTimestamp":1775248420,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker reported acquisition of 368,750 common shares on April 1, 2026.Disposals totaled 349,189 common shares on April 1-2, 2026 at prices of $24.04-$25.10 per share.Directly owned common shares stood at 19,561 following transactions.Derivative holdings included 1,106,250 capped value appreciation rights after transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL60pZnM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4588","BK4007","BK4585","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624863116","title":"Ro says working with Eli Lilly to launch Zepbound KwikPen","url":"https://stock-news.laohu8.com/highlight/detail?id=2624863116","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624863116?lang=en_us&edition=fundamental","pubTime":"2026-04-03 01:12","pubTimestamp":1775149939,"startTime":"0","endTime":"0","summary":"Direct-to-patient healthcare company Ro announced that it is working with Eli Lilly (LLY) to launch the recently FDA-approved Zepbound KwikPen nati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ro-says-working-with-eli-lilly-to-launch-zepbound-kwikpen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"80f30c1ff97a0a0fa49b25c6b2ccdaf7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ro-says-working-with-eli-lilly-to-launch-zepbound-kwikpen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0353189680.USD","LU2168564149.EUR","ELIS","LU2471134523.USD","LLYZ","SG9999015952.SGD","LU2417539215.USD","LU0943347566.SGD","IE00BFSS7M15.SGD","LU1323610961.USD","IE00B7KXQ091.USD","LU2236285917.USD","LU2552382215.SGD","LU1548497426.USD","LU0079474960.USD","SGXZ57979304.SGD","LU0106261372.USD","LU0225283273.USD","LU0640476718.USD","LU1127390331.HKD","LU2357305700.SGD","LU0256863902.USD","LU2361044865.SGD","LU1629891620.HKD","LU2896262040.SGD","IE00BFSS8Q28.SGD","BK4599","LU0786609619.USD","LU2108987350.USD","LU0096364046.USD","LU2112291526.USD","LU2106854487.HKD","LU2063271972.USD","LU2271345857.HKD","LU2471134796.USD","LU0820561818.USD","LU2456880835.USD","LU0006306889.USD","LU2361045086.USD","LU2756315664.SGD","LU2237443465.HKD","LU2168563687.JPY","LLY","LU2023250504.SGD","LU2237443978.SGD","LU0823434740.USD","LU0466842654.USD","LU2360106947.USD","LU1917777945.USD","LU0210536198.USD","LU2089984988.USD","IE0002141913.USD","LU0889565916.HKD","LU0122379950.USD","LU0456855351.SGD","LU2750360997.AUD","IE0001KFT4U8.USD","LU2462157665.USD","LU0353189763.USD","BK4007","SG9999001176.SGD","IE00BWXC8680.SGD","BK4585","SGXZ81514606.USD","IE00B775H168.HKD","SG9999015978.USD","IE00B2B36J28.USD","LU0158827781.USD","IE00B1BXHZ80.USD","LU0061475181.USD","LU2087625088.SGD","LU1232071149.USD","LU1061106388.HKD","LU2089284900.SGD","LU2491050154.USD","LU0787776722.HKD","LU0354030438.USD","LU0320765992.SGD","LU1057294990.SGD","LU2468319806.SGD","LU1267930730.SGD","LU0820562030.AUD","SG9999015945.SGD","LU1291159041.SGD","BK4516","LU1804176565.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU0094547139.USD","LU2264538146.SGD","LU0385154629.USD","SG9999014898.SGD","SG9999018857.SGD","LU0158827948.USD","LU0256863811.USD","VHT","LU1814569148.SGD","LU2211815571.USD","BK4533","IE00BJJMRZ35.SGD","LU0882574055.USD","LU1093756325.SGD","LU0683600562.USD","BK4581","LU2237438978.USD","SG9999015986.USD","LU0432979614.USD","LU2491050071.SGD","IE00BN29S564.USD","LU1720051017.SGD","LU0097036916.USD","LU1720051108.HKD","LU2237443549.SGD","SG9999014880.SGD","LU2111349929.HKD","LABU","SG9999014914.USD","IE00BJT1NW94.SGD","LU1145028129.USD","LU1035775433.USD","SG9999017495.SGD","LU1983299246.USD","GB00BDT5M118.USD","LU0238689110.USD","LU0823434583.USD","LU1551013425.SGD","IE00BJJMRY28.SGD","SG9999001176.USD","IE00BK4W5L77.USD","SGXZ99366536.SGD","LU1551013342.USD","LU0323591593.USD","LU1974910355.USD","LU1623119135.USD","SG9999014906.USD","LU2028103732.USD","SGXZ51526630.SGD","LU2168564222.USD","BK4588","LU0964807845.USD","SGXZ31699556.SGD","LU2168564065.EUR","LU0820561909.HKD","SG9999013999.USD","LU1868837136.USD","LU1868836914.USD","LU2023251221.USD","IE00BJLML261.HKD","LU2265009873.SGD","LU2023250330.USD","BK4534","LU0882574139.USD","LU2746668461.USD","LU0708995401.HKD","LU1366192091.USD","LU2491049909.HKD","LU0109391861.USD","LU1868836757.USD","IE00BK4W5M84.HKD","LU0203201768.USD","LU0289739699.SGD","LU0320765059.SGD","IE00BKDWB100.SGD","IE00B1XK9C88.USD","LU0354030511.USD","LU1093756168.USD","IE0005OL40V9.USD","LU1868837300.USD","BK4550","LU1989771016.USD","IE0004445015.USD","LU2237443895.HKD","LU2237443382.USD","ELIL","LU1988902786.USD","IE00B4JS1V06.HKD","LU0266013472.USD","IE0004445239.USD","LU2552382132.HKD","LU2471134952.CNY","LU2750360641.GBP","LU1064131342.USD","LU2089283258.USD","LU0109394709.USD","LU0203202063.USD","LU2168564495.EUR","LU2361044949.HKD","LU2552382058.USD","LU1868836591.USD","LU0316494557.USD","LU0114720955.EUR","LLII","LU0198837287.USD","LU2602419157.SGD","LU0234572021.USD","LU2213496289.HKD","LU0058720904.USD","IE00B4R5TH58.HKD","LU0471298777.SGD","LU0823416689.USD","LU0672654240.SGD","LU1280957306.USD","LU1712237335.SGD","IXJ","ROIV","LU0471298694.HKD","LU2756315318.SGD","LU2237443622.USD","IE0009355771.USD","IE00BKPKM429.USD","SG9999018865.SGD","LLYX","LU0417517546.SGD","LU2324357040.USD","LU2461242641.AUD","IE00BJJMRX11.SGD","LU2471134879.HKD","LU1069344957.HKD","LU2746668974.SGD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624685758","title":"BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2624685758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624685758?lang=en_us&edition=fundamental","pubTime":"2026-04-03 01:08","pubTimestamp":1775149715,"startTime":"0","endTime":"0","summary":"BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its PlatformApril 2 (Reuters) - Ro:RO: WORKING WITH ELI LILLY TO LAUNCH ZEPBOUND KWIKPEN NATIONWIDE ON ITS PLATFORM ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"80f30c1ff97a0a0fa49b25c6b2ccdaf7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L10E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU2357305700.SGD","LU0058720904.USD","SGXZ81514606.USD","LU1868836914.USD","LU2108987350.USD","LU2361044949.HKD","BK4534","LU2552382215.SGD","LU2462157665.USD","LU0198837287.USD","IE00B7KXQ091.USD","LLYX","LU0109394709.USD","IE00B4R5TH58.HKD","LU2456880835.USD","LU2471134523.USD","LU2552382058.USD","ROIV","BK4516","LU2237443382.USD","LU0354030438.USD","LU1814569148.SGD","LU1069344957.HKD","SG9999017495.SGD","SG9999015978.USD","BK4533","LU2211815571.USD","LU0882574055.USD","LU2106854487.HKD","LU2237443549.SGD","LU1804176565.USD","LU2750360997.AUD","SG9999001176.SGD","LU0823434583.USD","LU2087625088.SGD","IE00B775H168.HKD","LU0823416689.USD","LU2023250504.SGD","IE00BKPKM429.USD","LU0256863811.USD","LU1291159041.SGD","LU0158827781.USD","IE0004445239.USD","IE00BK4W5L77.USD","LU0820561909.HKD","IE0002141913.USD","LU2168564222.USD","LU0097036916.USD","SG9999013999.USD","LU1629891620.HKD","LU2324357040.USD","LU0094547139.USD","LU0640476718.USD","LU1868836591.USD","LU0353189763.USD","LU0672654240.SGD","IE0004445015.USD","BK4599","LU2028103732.USD","LU2271345857.HKD","LU2237438978.USD","LU2168564495.EUR","SG9999014906.USD","SGXZ57979304.SGD","LU1064131342.USD","LU1548497426.USD","SG9999018857.SGD","LU1868836757.USD","LU1551013342.USD","LU0320765059.SGD","IE00BWXC8680.SGD","LU0106261372.USD","LU2491050071.SGD","LU1712237335.SGD","LU2756315318.SGD","LU2236285917.USD","LU2213496289.HKD","LU2746668461.USD","ELIS","IE00B4JS1V06.HKD","LU1267930730.SGD","SG9999014898.SGD","SG9999001176.USD","LU0256863902.USD","LU1232071149.USD","LU2168564149.EUR","LU0964807845.USD","LU0432979614.USD","LU1145028129.USD","IE0009355771.USD","ELIL","LU0683600562.USD","LU2746668974.SGD","LU1720051108.HKD","LU1974910355.USD","LU2023251221.USD","LU2361044865.SGD","IE0001KFT4U8.USD","LU0820562030.AUD","LU1127390331.HKD","LU0079474960.USD","LU0109391861.USD","IE00BJJMRY28.SGD","LU2750360641.GBP","LU1093756168.USD","IE00BJLML261.HKD","LU2237443465.HKD","SG9999018865.SGD","LU2360106947.USD","LU1280957306.USD","IE00B2B36J28.USD","LU2491050154.USD","LU2471134879.HKD","LU0354030511.USD","LU1868837300.USD","LU0114720955.EUR","LU0006306889.USD","LU0203201768.USD","LU1623119135.USD","LU0225283273.USD","LU1868837136.USD","LU1989771016.USD","IE00BKDWB100.SGD","LU2237443895.HKD","IE00B1XK9C88.USD","LLII","LU2089283258.USD","LU0466842654.USD","IE00BFTCPJ56.SGD","LU0234572021.USD","SG9999014880.SGD","IE00BFSS7M15.SGD","IE00BJJMRX11.SGD","LU0289739699.SGD","LU0787776722.HKD","LU2111349929.HKD","LLYZ","LU0061475181.USD","LU0316494557.USD","LU0820561818.USD","LU1917777945.USD","LU2237443978.SGD","LU1720051017.SGD","LU2168563687.JPY","LU0210536198.USD","BK4585","LU1035775433.USD","LU0323591593.USD","IE00BJJMRZ35.SGD","IE00BK4W5M84.HKD","LU2089284900.SGD","LU0320765992.SGD","LU0417517546.SGD","BK4581","SG9999015952.SGD","LU0786609619.USD","SG9999014914.USD","LU0471298694.HKD","LU1366192091.USD","SGXZ31699556.SGD","LU0238689110.USD","LU1988902786.USD","LU1551013425.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU2552382132.HKD","BK4588","LU2264538146.SGD","LU0353189680.USD","LU0823434740.USD","LU1061106388.HKD","LU2461242641.AUD","LU2417539215.USD","LU0385154629.USD","LU2063271972.USD","LU2471134796.USD","GB00BDT5M118.USD","LU0471298777.SGD","LU1323610961.USD","LU2237443622.USD","LU1983299246.USD","LLY","LU2491049909.HKD","LU0456855351.SGD","LU1093756325.SGD","LU0882574139.USD","LU2265009873.SGD","LU0889565916.HKD","LU2756315664.SGD","LU2896262040.SGD","LU0203202063.USD","LU0158827948.USD","LU0689472784.USD","IE00BJT1NW94.SGD","LU2089984988.USD","LU0096364046.USD","LU2168564065.EUR","SG9999015945.SGD","LU1023059063.AUD","LU0122379950.USD","LU2471134952.CNY","SGXZ99366536.SGD","LU2602419157.SGD","LU2361045086.USD","SG9999015986.USD","LU0266013472.USD","IE00BN29S564.USD","LU2023250330.USD","SGXZ51526630.SGD","IE0005OL40V9.USD","IE00BFSS8Q28.SGD","LU0708995401.HKD","LU2112291526.USD","LU2468319806.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624749195","title":"Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2624749195","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624749195?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120441,"startTime":"0","endTime":"0","summary":"Immunovant reported topline results from two Phase 3 studies of batoclimab in thyroid eye disease, with results already presented in this update.Both trials missed primary endpoint, raising uncertainty around batoclimab commercial prospects in thyroid eye disease.Safety profile matched prior studies, with no new safety signals flagged.Immunovant shifted emphasis to IMVT-1402 development across autoimmune diseases, with Graves’ disease positioned as key priority.Topline data from potentially registrational IMVT-1402 studies in Graves’ disease expected in calendar year 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3Mp9Mk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","BK4007","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","IMVT","ROIV","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574917","title":"Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574917?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120428,"startTime":"0","endTime":"0","summary":"Priovant, backed by Roivant, began enrolling subjects in a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first patients enrolled in March 2026.Prior results have already been reported from an investigator-initiated, placebo-controlled study that supported moving brepocitinib into rapid development for this indication.Program targets a scalp disorder that can cause generally irreversible scarring hair loss with significant pain and itching, with no FDA-approved treatments.Expansion adds a fourth late-stage indication for brepocitinib, extending strategy to build a multi-indication rare rheumatology-dermatology franchise ahead of an expected dermatomyositis launch in September.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLb6YlNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BN0W2W23.USD","SG9999014039.USD","SG9999014005.SGD","BK4007","NDAQ","BK4112","BK4139","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","ROIV","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.0429},{"period":"3month","weight":0.0539},{"period":"6month","weight":0.4036},{"period":"1year","weight":1.646},{"period":"ytd","weight":0.3157}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.027057},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}